ASCO: Fotemustine Prolongs Survival in Patients with Liver Metastases from Ocular Melanoma
ORLANDO, FL — May 20, 2002 — Fotemustine demonstrated activity against liver metastases from ocular melanoma and increased median survival to 14.8 months, according to
